Impact of comorbidities, diabetes, and smoking on sustained outcomes in rheumatoid arthritis: a retrospective study
- PMID: 40485943
- PMCID: PMC12138991
- DOI: 10.5114/reum/199933
Impact of comorbidities, diabetes, and smoking on sustained outcomes in rheumatoid arthritis: a retrospective study
Abstract
Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease significantly impacting patients' quality of life (QoL) and necessitating complex, long-term treatment. This study aimed to assess the long-term therapeutic outcomes of biologic therapies in a real-world clinical setting, focusing on the achievement and maintenance of low disease activity (LDA) among RA patients, while also investigating factors influencing these outcomes.
Material and methods: A retrospective observational analysis was conducted on 190 RA patients receiving tumor necrosis factor α (TNF-α) or interleukin (IL)-6 inhibitors. Disease activity was evaluated using the Disease Activity Score 28 (DAS28) at baseline, 6 months, and 12 months. Based on the DAS28 with C-reactive protein (DAS28-CRP) values, the disease was categorized into 2 main groups: remission/low activity (target achieved) when the DAS28-CRP value was less than 3.2, and insufficient therapeutic response when the value exceeded 3.2.
Results: The study group consisted of 190 RA patients, predominantly women (85.8%), with a mean age of 58.7 years and a disease duration of 12.5 years. We found that 45.8% of patients achieved single-point LDA, with 39.5% sustaining this response after 12 months. Notably, comorbidities such as diabetes and smoking negatively affected the likelihood of maintaining LDA. Statistical analysis revealed that patients without diabetes had a significantly higher chance of retaining sustained LDA (OR = 0.100; p = 0.014).
Conclusions: These findings emphasize the need for personalized treatment approaches that consider comorbidities and lifestyle factors to enhance long-term therapeutic efficacy in RA management. Consequently, this study highlights the critical importance of ongoing monitoring and individualized strategies to improve outcomes and QoL for patients with RA.
Keywords: biological therapy; comorbidity; rheumatoid arthritis; smoking.
Copyright: © 2025 Termedia & Banach.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Effectiveness and Predictors of Long-Term Treatment Response to Tofacitinib in Rheumatoid Arthritis Cohort: General Analysis and Focus on High-Cardiovascular-Risk Subgroup-A Multicenter Study.Medicina (Kaunas). 2024 Dec 2;60(12):1982. doi: 10.3390/medicina60121982. Medicina (Kaunas). 2024. PMID: 39768862 Free PMC article.
-
Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study.Arthritis Res Ther. 2025 Apr 10;27(1):84. doi: 10.1186/s13075-025-03528-5. Arthritis Res Ther. 2025. PMID: 40211417 Free PMC article.
-
Semi-quantitative analysis of 18F fluorodeoxyglucose uptake in the assessment of disease activity and therapeutic response in rheumatoid arthritis: An institutional experience.World J Nucl Med. 2020 Jun 27;19(4):347-352. doi: 10.4103/wjnm.WJNM_12_20. eCollection 2020 Oct-Dec. World J Nucl Med. 2020. PMID: 33623503 Free PMC article.
-
Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation.Health Technol Assess. 2021 Feb;25(8):1-248. doi: 10.3310/hta25080. Health Technol Assess. 2021. PMID: 33555998 Free PMC article.
-
Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme.Southampton (UK): NIHR Journals Library; 2021 Aug. Southampton (UK): NIHR Journals Library; 2021 Aug. PMID: 34406722 Free Books & Documents. Review.
References
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous